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can improve compliance (Hill et al., 2011) . In one study, administration compliance was only 65% with oral carbimazole versus 100% for transdermal methimazole (Hill et al., 2011) . However, not all medications are suitable to transdermal application. The pharmacokinetics of transdermal amlodipine, amitriptyline, buspirone, cyclosporine, dexamethasone, fluoxetine, methimazole, mirtazapine, ondansetron, and phenobarbital have been studied (Hoffmann, Marks, Taboada, Hosgood, & Wolfsheimer, 2003; Mealey et al., 2004; Helms, 2007; Hill et al., 2011; Delamaide Gasper, Barnes Heller, Robertson, & Trepanier, 2015; Benson, Zajic et al., 2017; Eichstadt et al., 2017; Zajic et al., 2017) . Of these, transdermal methimazole and mirtazapine have demonstrated the most promise to achieve therapeutic blood concentrations and result in a pharmacodynamic effect (Hoffman, Yoder, & Trepanier, 2002; Hoffmann et al., 2003; Hill et al., 2011; Boretti et al., 2014; Benson, Zajic et al., 2017; Quimby, Summers, Benson, Herndon, & Gustafson, 2017) . The objective of these studies was to evaluate the pharmacokinetics (PK) of a novel, 
| MATERIAL S AND ME THODS
| Cats
Cats were selected from the Vivocore Inc. (Fergus, Ontario, Canada) large cat colony where cats were housed multiple cats per room.
Vivocore Inc. obtained purpose-bred, out-bred, domestic short hair or long hair cats from Liberty Research, Inc. (Waverly, NY) for these studies. Study 1 and Study 2 used different cats from the same purpose-bred facility. Eligible laboratory cats had to be apparently healthy, as determined by physical examination and unremarkable CBC and clinical chemistry performed on Day-7, be manageable and cooperative with study procedures, have two accessible jugular veins, and have not participated in another drug trial for at least 2 weeks. Cats were excluded if they were less than 2 kg in weight, were pregnant or lactating, had fractious behavior, or had any medical or surgical condition requiring treatment or intervention.
During study activities, cats were housed in individual cages in compliance with current recommendations of the Guide for the Care and Use of Laboratory Animals, under the standard operating procedures (SOPs) of the test facility, and according to the approved test facility Institutional Animal Care and Use Committee (IACUC) for protocol identifiers VRI92-15061-FP (KB103PK) and VRI92-15083-FP (KB111PK). Cats were acclimated from Day -7 to Day -1 to cages and feed and management practices that were maintained throughout the study. Cats were fed commercial dry cat chow ad libitum and were dosed with study drug without regard to fed state.
Water was provided ad libitum with bowls filled at least twice daily.
Elizabethan collars were worn throughout both studies in all cats to minimize ear grooming. Cats were acclimatized to the Elizabethan collar for 7 days prior to the first dosing event.
| Drug product and administration
The drug product consisted of a novel mirtazapine transdermal ointment formulation intended for transdermal (topical) use only. Each 1 g of ointment contains 20 mg mirtazapine (2% mirtazapine, active;
i.e., approximately 2 mg/0.1 ml). The formulation contains the following inactive ingredients: polyethylene glycol (PEG) 400, PEG 3350, diethylene glycol monoethyl ether, PEG-8 caprylic/capric glycerides, oleyl alcohol, butylated hydroxytoluene, dimethicone, and Dry Flo TS. A single dose of ointment was administered orally in the single dose study solely for the purpose of a control dose to assess the relative bioavailability of the transdermal compared to the oral as there is no appropriate IV mirtazapine formulation. Calculated dose volumes were determined by weight and drawn up in a separate 1.0 ml tuberculin syringe for each cat. Cats were dosed at 0.5 mg/kg which was selected based on the dose of oral mirtazapine (0.27-0.64 mg/ kg) that was previously reported to achieve a pharmacodynamic effect (Quimby, Gustafson, Samber et al., 2011) . Once-daily administration was selected based on a previous study in which daily administration of 1.88 mg mirtazapine to young normal cats resulted in negligible drug accumulation, and thus daily would be the shortest clinically applicable dosing interval (Quimby, Gustafson, Samber et al., 2011) . Cats were dosed by application of the calculated volume of ointment onto the inner (anterior) surface of the right pinna followed by rubbing and spreading of the ointment to cover the surface area of the pinna. Ear cleaning between doses was not performed in the multiple dose study.
The oral administration consisted of opening the cats' mouth and inserting the syringe to the back of the pharynx.
| Study 1
This was a randomized, cross-over single dose pilot PK study. Eight apparently healthy purpose-bred adult cats with unremarkable physical examination, CBC and serum biochemistry were used and were acclimated to study conditions for seven days prior to dosing. All eight cats were domestic shorthairs; two neutered males and six spayed females. Ages ranged from 6.0 to 12.3 years (median 10.2 years) and body weight on Day 0 ranged from 2.5 to 8.7 kg (median 5.1 kg). Cats were randomized to treatment group per a sequence provided by the sponsor and stratified based on sex. On Day 0, four cats were randomly assigned to Group A and treated with 0.5 mg/kg of mirtazapine transdermal ointment administered orally, and four cats were randomly assigned to Group B were treated with 0.5 mg/kg of mirtazapine transdermal ointment applied onto the right ear pinna.
Blood samples were collected predose and at 1, 2, 4, 6, 8, 12, 24, 48, 72 , and 96 hr postdose. On Day 5, ten half-lives from the initial Day 0 dose, the two groups crossed over to the opposite treatment and the same blood sampling regimen was performed. On Day 5 in Study 1, prior to the second dose, all cats had mirtazapine levels below quantifiable limits.
| Study 2
This was a multiple dose PK study. Eight apparently healthy purposebred adult cats with unremarkable physical examination, CBC and serum biochemistry were used. All eight cats were domestic short hairs; four neutered males and four spayed females. Ages ranged from 6.3 to 13.0 years (median 7.3 years) and body weight on Day -1 ranged from 3.7-7.3 kg (median 5.3 kg). Cats received once-daily transdermal application of 0.5 mg/kg mirtazapine transdermal ointment on Day 0 through Day 13. Blood samples were collected predose and at 1, 2, 4, 6, 8, 12, 24, 48, 72 , and 96 hr after the final Day 13 administration of mirtazapine.
| Blood collection
Colony cats were trained to be accustomed to handling and veni- and transferred into a 3 ml evacuated tube containing K 2 EDTA as an anticoagulant. Blood tubes were held on ice and within 2 hr of collection, each blood tube was processed by refrigerated centrifugation (~720 g; 4°C; 10 min). After centrifugation, plasma was aspirated with a disposable pipet, and ~0.25 ml volume was transferred to cryovials. Plasma samples were held in frozen storage at ≤−20°C until shipped (on dry ice to maintain frozen state) to the analytical laboratory. calibration range of the method was 0.500-500 ng/ml for mirtazapine using a 25 μl sample aliquot. Accuracy of calibration curve standards within ±15.0% (±20.0% at LLOQ) of the nominal concentration was achieved. Mean intra-and inter-run accuracy of quality control samples were within ±15.0% (±20.0% at the LLOQ) of the nominal concentration and precision was ≤15.0% (≤20.0% at the LLOQ).
| Mirtazapine analysis
Mirtazapine was also demonstrated to be stable during storage, processing, and analysis.
| Plasma pharmacokinetic analysis and statistical methods
Pharmacokinetic parameters were calculated using standard noncompartmental methods. The following plasma PK parame- 
| Study 2
The mean plasma concentration-time profile of mirtazapine following multiple dose transdermal application is graphically displayed in Figure 2 . The pharmacokinetic parameters are presented in Table 2 .
Average concentration over the dosing interval was 16.4 ng/ml and the mean fluctuation in plasma concentrations over the dosing interval was 210%. The mean (±standard deviation (SD)) calculated halflife of transdermal mirtazapine after 14 days of daily administration was 20.7 (4.0) h. Some cats experienced mild redness of the skin of the pinna after multiple day dosing.
| D ISCUSS I ON
Based upon the results of these two PK studies, the transdermal ap- The pinna of the cats' ear has been chosen in many studies as the preferred transdermal application site as it has been shown that drugs are well absorbed through the skin for systemic action (Ciribassi et al., 2003; Hoffmann et al., 2003; Mealey et al., 2004; Sartor, Trepanier, Kroll, Rodan, & Challoner, 2004; Bennett, Papich, Hoenig, Fettman, & Lappin, 2005; Lecuyer, Prini, Dunn, & Doucet, 2006; Helms, 2007; Hill et al., 2015) . The inner pinna of the cats' ear is ideally suited to transdermal medications as it is hairless and highly vascular. In addition, the inner surface of the pinna cannot be directly licked during grooming making oral ingestion of the full TA B L E 1 PK parameters of mirtazapine following a single dose of mirtazapine transdermal ointment applied transdermally and administered orally (Study 1) cats using this formulation applied transdermally to the inner pinna at 2 mg per cat without use of an Elizabethan collar, there were no signs of toxicity noted (Longpre et al., 2017) .
The PK of mirtazapine in cats has been previously described for an oral capsule formulation in healthy young cats, healthy geriatric cats, and cats with chronic kidney disease, as well as for transdermal lipoderm gel in healthy young cats (Tables 3 and 4) Quimby, Gustafson, Samber et al., 2011; Benson et al., 2017) . Meaningful comparisons between studies with different formulations and populations of cats from various sites are limited, however, the following discussion relates to general concepts. In Study 1, a single oral dose of mirtazapine transdermal ointment was administered at a mg/kg dose similar to that administered in previous PK studies of the oral 1.88 mg capsule formulation of mirtazapine (Table 3 ) and plasma AUC 0-∞ in Study 1 (434 ± 149 ng*h/ ml) was generally comparable with serum AUC 0-∞ (407.4 ± 102.1) from the previously published PK study (Quimby, Gustafson, Samber et al., 2011) . The mean AUC 0-24 of cats administered mirtazapine transdermal ointment daily in Study 2 (400 ± 100 ng*h/ml) was generally comparable to mean AUC 0-24 of cats who had a demonstrable increase in appetite after single dose administration of 1.88 mg F I G U R E 1 a & b Drug concentration curves (±SD) for cats after single dose oral administration (Figure 1a ) and the transdermal application of mirtazapine ointment (0.5 mg/kg) (Figure 1b) . Note that following transdermal application, mirtazapine absorption was relatively slow (compared to oral administration) F I G U R E 2 Day 13 drug concentration curves (±SD) for cats after daily transdermal application of mirtazapine ointment (0.5 mg/kg). All cats had quantifiable (trough levels at steady state) mirtazapine levels at Time 0 on Day 13 mirtazapine (440.2 ± 137.5 ng*h/ml) (Quimby, Gustafson, Samber et al., 2011) .
For single dose transdermal application of mirtazapine ointment in healthy young cats, serum PK parameters seen in a previously published study were again generally comparable with that reported in Study 1 (Table 4) . However, the previously reported lipoderm gel formulation appeared to produce a somewhat flatter drug concentration curve and thus a lower mean C max compared to the novel ointment formulation, even at a higher mg/ kg dose. Additionally, a half-life could not be calculated for the lipoderm product due to the variable absorption and resulting atypical drug concentration curve.
Limitations of the PK data presented here are that they were obtained from two separate groups of apparently healthy cats of varying sex and age, and as urinalyses were not performed, the presence of early renal insufficiency could not be ruled out. Although this limitation exists, the population of cats used is representative of the target population of client-owned cats in veterinary practice likely to be treated with mirtazapine transdermal ointment. In previous studies, completed by Quimby and colleagues, they found that cats with chronic kidney disease, and to a lesser extent geriatric healthy cats, had a delayed clearance of oral mirtazapine (Table 3 ) . In human studies, liver and moderate renal impairment causes a 30% decrease in clearance and severe renal impairment causes a 50% decrease in clearance (Timmer, Sitsen, & Delbressine, 2000) . TA B L E 4 Mirtazapine plasma or serum PK parameters from a published study and the Study 1 study after single dose transdermal application limitation of the study was that doses of ointment were measured and dispensed using a tuberculin syringe and variability in dose could have occurred; however, the dosing methodology was chosen because of its clinical relevance. Ear cleaning between doses was not performed during the multiple dose study. This may have had an effect on potential drug accumulation as well as resulted in residual drug on the ear. Pharmacodynamic (PD) effects were not reported in this study. As the primary endpoint of the studies was PK, the study was not designed to be powered for PD effects and thus data were not included as meaningful conclusions could not be drawn. However, as previously discussed, mean AUC 0-24 after 14 days administration of mirtazapine transdermal ointment was generally comparable to the mean AUC 0-24 of oral mirtazapine studies in which PD was performed (Quimby, Gustafson, Samber et al., 2011) .
Single and repeat doses of a novel mirtazapine transdermal ointment applied to the inner pinna of the ear achieve lower mean peak (C max ) and total (AUC) plasma exposure measures than oral dosing, whereas mean total exposure was somewhat more comparable between the two routes of administration. Repeat daily topical dosing provided higher mean peak and total plasma exposure measures, when compared to single topical dosing.
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